Enovis Corporation (NYSE:ENOV) Stock Has Consensus Price Target of $39.50 According to Brokerages

Key Points

• Analysts maintain a Moderate Buy consensus on Enovis, with 10 buy ratings, one hold and one sell among 12 firms. The average 12-month price target is $39.50, well above the stock’s reported $18.20 price.
• Enovis exceeded quarterly expectations, reporting $0.90 in adjusted EPS versus the $0.85 estimate and $582.78 million in revenue versus $581.84 million expected; revenue rose 3.2% year over year.
• Insiders have been buying shares: the CEO and another insider made purchases totaling roughly $350,000, while insiders acquired 23,293 shares worth $449,599 over the past 90 days. Institutional investors own 98.45% of the company.

Shares of Enovis Corporation (NYSE:ENOV - Get Free Report) have been given a consensus rating of "Moderate Buy" by the twelve research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $39.50.

Several equities research analysts have recently commented on ENOV shares. Weiss Ratings raised shares of Enovis from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, July 21st. Citigroup reiterated a "market outperform" rating on shares of Enovis in a research note on Wednesday, September 2nd. BMO Capital Markets set a $27.00 price objective on Enovis in a report on Tuesday, September 1st. BTIG Research lowered their price objective on Enovis from $40.00 to $36.00 and set a "buy" rating for the company in a research note on Tuesday, September 1st. Finally, UBS Group reaffirmed a "buy" rating and set a $44.00 target price on shares of Enovis in a research report on Monday.

Enovis Price Performance

Shares of NYSE:ENOV opened at $18.20 on Wednesday. Enovis has a twelve month low of $17.30 and a twelve month high of $34.28. The stock's 50 day moving average is $22.46 and its 200-day moving average is $23.39. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -0.94 and a beta of 1.37.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The business had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. During the same quarter in the previous year, the business posted $0.79 EPS. Enovis's quarterly revenue was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts forecast that Enovis will post 3.15 EPS for the current fiscal year.

Insider Buying and Selling at Enovis

In other news, insider Oliver Engert bought 5,140 shares of Enovis stock in a transaction dated Thursday, September 3rd. The stock was purchased at an average price of $19.46 per share, for a total transaction of $100,024.40. Following the purchase, the insider directly owned 61,238 shares in the company, valued at $1,191,691.48. The trade was a 9.16% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Damien Mcdonald bought 13,035 shares of the stock in a transaction dated Friday, September 4th. The stock was purchased at an average price of $19.15 per share, with a total value of $249,620.25. Following the acquisition, the chief executive officer owned 247,077 shares of the company's stock, valued at $4,731,524.55. The trade was a 5.57% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have acquired 23,293 shares of company stock worth $449,599. Company insiders own 2.90% of the company's stock.

Institutional Investors Weigh In On Enovis

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Paradigm Capital Management Inc. NY grew its holdings in shares of Enovis by 70.2% in the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company's stock valued at $40,420,000 after acquiring an additional 732,917 shares in the last quarter. River Road Asset Management LLC lifted its holdings in Enovis by 3.2% during the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company's stock worth $39,621,000 after acquiring an additional 46,289 shares during the period. Private Management Group Inc. boosted its position in Enovis by 38.8% in the second quarter. Private Management Group Inc. now owns 1,365,082 shares of the company's stock worth $28,257,000 after purchasing an additional 381,705 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in Enovis by 38.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company's stock valued at $24,430,000 after purchasing an additional 287,687 shares during the period. Finally, Invenomic Capital Management LP increased its position in shares of Enovis by 6.2% during the 4th quarter. Invenomic Capital Management LP now owns 756,717 shares of the company's stock valued at $20,159,000 after purchasing an additional 44,048 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company's stock.

About Enovis

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient outcomes and support the restoration of movement. Its portfolio serves orthopedic, rehabilitation and recovery markets, with products used by physicians, hospitals, physical therapists, athletic trainers and consumers.

The company's offerings include orthopedic braces and supports, cold and compression therapy systems, rehabilitation equipment, electrical stimulation and ultrasound products, surgical implants and related technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.